Moody Aldrich Partners LLC Sells 14,928 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Moody Aldrich Partners LLC trimmed its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 11.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 119,287 shares of the company's stock after selling 14,928 shares during the period. Moody Aldrich Partners LLC owned 0.20% of Protagonist Therapeutics worth $5,368,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in PTGX. GAMMA Investing LLC boosted its position in shares of Protagonist Therapeutics by 749.2% in the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company's stock worth $25,000 after purchasing an additional 487 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in Protagonist Therapeutics by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 34,895 shares of the company's stock valued at $1,010,000 after buying an additional 849 shares during the last quarter. Exchange Traded Concepts LLC bought a new stake in Protagonist Therapeutics in the third quarter worth $43,000. CWM LLC grew its stake in shares of Protagonist Therapeutics by 910.3% in the third quarter. CWM LLC now owns 1,273 shares of the company's stock worth $57,000 after acquiring an additional 1,147 shares during the last quarter. Finally, ProShare Advisors LLC increased its holdings in shares of Protagonist Therapeutics by 9.2% during the first quarter. ProShare Advisors LLC now owns 14,345 shares of the company's stock valued at $415,000 after acquiring an additional 1,206 shares in the last quarter. Institutional investors own 98.63% of the company's stock.

Wall Street Analyst Weigh In

PTGX has been the topic of several recent analyst reports. BTIG Research increased their price objective on shares of Protagonist Therapeutics from $41.00 to $51.00 and gave the company a "buy" rating in a research report on Wednesday, July 24th. JMP Securities cut their price target on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a "market outperform" rating on the stock in a report on Wednesday, August 7th. TD Cowen raised shares of Protagonist Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 25th. Truist Financial initiated coverage on Protagonist Therapeutics in a research report on Monday, September 9th. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their target price on Protagonist Therapeutics from $39.00 to $48.00 and gave the stock an "overweight" rating in a report on Thursday, July 25th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $49.86.

Insider Activity

In related news, Director William D. Waddill sold 8,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total value of $360,000.00. Following the transaction, the director now owns 12,000 shares of the company's stock, valued at approximately $540,000. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director William D. Waddill sold 8,000 shares of the firm's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total value of $360,000.00. Following the transaction, the director now directly owns 12,000 shares of the company's stock, valued at approximately $540,000. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Asif Ali sold 14,203 shares of Protagonist Therapeutics stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total value of $631,891.47. Following the transaction, the chief financial officer now owns 34,960 shares in the company, valued at $1,555,370.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.40% of the company's stock.

Protagonist Therapeutics Trading Up 0.8 %

NASDAQ:PTGX traded up $0.36 during trading hours on Thursday, reaching $46.95. The company had a trading volume of 283,503 shares, compared to its average volume of 747,886. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of 17.92 and a beta of 2.17. The firm's 50 day moving average price is $44.40 and its 200-day moving average price is $36.47. Protagonist Therapeutics, Inc. has a 52 week low of $13.72 and a 52 week high of $48.32.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.50) EPS for the quarter, hitting the consensus estimate of ($0.50). The firm had revenue of $4.17 million during the quarter, compared to the consensus estimate of $40.00 million. On average, analysts forecast that Protagonist Therapeutics, Inc. will post 2.32 earnings per share for the current fiscal year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.